147 related articles for article (PubMed ID: 7734313)
21. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.
di Pietro A; Vries EG; Gietema JA; Spierings DC; de Jong S
Int J Biochem Cell Biol; 2005 Dec; 37(12):2437-56. PubMed ID: 16099193
[TBL] [Abstract][Full Text] [Related]
22. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
23. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Anticancer Drugs; 1996 Sep; 7(7):795-9. PubMed ID: 8949993
[TBL] [Abstract][Full Text] [Related]
24. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
Kollmannsberger C; Mayer F; Kuczyk M; Kanz L; Bokemeyer C
World J Urol; 2001 Apr; 19(2):120-5. PubMed ID: 11374314
[TBL] [Abstract][Full Text] [Related]
25. Long-term complications of chemotherapy for germ cell tumours.
Chaudhary UB; Haldas JR
Drugs; 2003; 63(15):1565-77. PubMed ID: 12887263
[TBL] [Abstract][Full Text] [Related]
26. O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines.
Walker MC; Masters JR; Margison GP
Br J Cancer; 1992 Nov; 66(5):840-3. PubMed ID: 1419626
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro.
Koch S; Mayer F; Honecker F; Schittenhelm M; Bokemeyer C
Br J Cancer; 2003 Dec; 89(11):2133-9. PubMed ID: 14647149
[TBL] [Abstract][Full Text] [Related]
28. Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies.
Parris CN; Walker MC; Masters JR; Arlett CF
Cancer Res; 1990 Dec; 50(23):7513-8. PubMed ID: 2253200
[TBL] [Abstract][Full Text] [Related]
29. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.
Shelley MD; Burgon K; Mason MD
Cancer Treat Rev; 2002 Oct; 28(5):237-53. PubMed ID: 12435371
[TBL] [Abstract][Full Text] [Related]
30. Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.
de Graaf TW; de Jong S; de Vries EG; Mulder NH
Anticancer Res; 1997; 17(1A):369-75. PubMed ID: 9066679
[TBL] [Abstract][Full Text] [Related]
31. Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells.
Reinhold U; Ugurel S; Tilgen W; Kadiata MM; Olivares E; Nadi AB; Malaisse WJ
Oncol Rep; 2000; 7(5):1093-7. PubMed ID: 10948345
[TBL] [Abstract][Full Text] [Related]
32. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
Spierings DC; de Vries EG; Vellenga E; de Jong S
Cell Death Differ; 2003 Jul; 10(7):808-22. PubMed ID: 12815464
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report.
Sokol DB; Hudes GR
Am J Clin Oncol; 1998 Aug; 21(4):420-1. PubMed ID: 9708647
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis.
Arriola EL; Rodriguez-Lopez AM; Hickman JA; Chresta CM
Oncogene; 1999 Feb; 18(7):1457-64. PubMed ID: 10050882
[TBL] [Abstract][Full Text] [Related]
35. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
[TBL] [Abstract][Full Text] [Related]
36. Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents.
Bokemeyer C; Dunn T; Harstrick A; Lerch T; Poliwoda H; Schmoll HJ
Int J Cancer; 1994 Feb; 56(3):452-6. PubMed ID: 7906255
[TBL] [Abstract][Full Text] [Related]
37. Curing metastatic cancer: lessons from testicular germ-cell tumours.
Masters JR; Köberle B
Nat Rev Cancer; 2003 Jul; 3(7):517-25. PubMed ID: 12835671
[TBL] [Abstract][Full Text] [Related]
38. Activity of temozolomide against human tumor colony-forming units.
Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
[TBL] [Abstract][Full Text] [Related]
39. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
40. Seladin-1 and testicular germ cell tumours: new insights into cisplatin responsiveness.
Nuti F; Luciani P; Marinari E; Erdei E; Bak M; Deledda C; Rosati F; Mazzinghi B; Danza G; Stoop H; Looijenga LH; Peri A; Serio M; Krausz C
J Pathol; 2009 Dec; 219(4):491-500. PubMed ID: 19844922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
